Healthy
Conditions
Keywords
Healthy, Risperdal OD, Risperdal Quicklet, Korea
Brief summary
The purpose of this study was to conduct the bioequivalence (biological equivalence of two preparations of a drug) test in healthy adults with Risperdal OD Tab. 2mg of Janssen Korea as the investigational drug and Risperdal Quicklet Tab. 2mg as the control drug.
Detailed description
This was a randomized (the study drug is assigned by chance) and open labeled (all people know the identity of the intervention) study. All participants were hospitalized in research rooms and were subsequently restricted in exercise, eating, drinking, smoking and xanthine-beverages until the end of blood collection. Water was allowed to be taken until one hour before drug administration. Participants were randomly assigned into two groups, one group receiving Risperdal OD (investigational drug), and one group receiving Risperdal Quicklet (control drug). On the day of testing, blood was collected from all participants to provide baseline measurements. Subsequently, the study drug was orally administered to the participants, followed by blood collection of a total of 13 time points, up to 24 hours. After the blood collection was finished, participants were discharged after receiving proper guidance and being examined by a psychologist. Following a wash-out period (period when receiving no intervention) of one week, participants were hospitalized once more and crossed over to receive the study drugs following the same procedure above described. The approximate study duration (including the drug administration days and wash-out period) was approximately 10 days.
Interventions
DRUGRisperdal OD Tab. 2mg
1 tablet Risperdal OD 2 mg administered orally.
DRUGRisperdal Quicklet Tab. 2mg
1 tablet Risperdal Quicklet Tab. 2mg administered orally.
Sponsors
Janssen Korea, Ltd., Korea
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy Korean participants weighing more than 50kg and within 20% normal lean body weight (standard weight) * Participant without congenital or chronic diseases and with no symptoms or findings as a result of internal examination * Participant who was deemed appropriate as a result of inquiry, blood pressure, physical examination, electrocardiogram, blood and urinalysis, etc., within 28 days prior to the first administration of the investigational drug according to the protocol * Female participant who was confirmed as non-pregnant through urine test during health examination
Exclusion criteria
* Participant who had a history of disease related to cardiac, respiratory, hepatic, renal, gastrointestinal or nervous system, or cardiac infarction, stroke, hypertension, arrhythmia, coronary artery disease, or neuropsychiatric diseases that could affect drug absorption, distribution, metabolism and excretion or could be risk factors when taking drugs used for the clinical trial, a history of gastrointestinal surgery except appendectomy or herniotomy, or who currently had abnormality in inquiry or physical examination * Participant who showed symptoms that were suspected as acute disease within 14 days from the first administration of the investigational drug * Participant with allergic disease requiring treatment * Participant who had a history of being hypersensitive to drugs or food * Patient who had hepatitis B antigen or who showed hepatitis C positive antigen
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentrations of Risperidone | Up to 24 hours postdose |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events as a measure of safety | Approximately 10 days |
Outcome results
None listed